1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Luye Pharma Group Ltd.

Luye Pharma Group Ltd.

LYPHF
Luye Pharma Group Ltd.US flagOther OTC
0.20
USD
- -
- -
815.28MMarket Cap
Luye Pharma Group Ltd.
LYPHF
(Other OTC)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.94
2.72
3.6
5.1
0.85
0.77
0.88
1.17
1.61
1.98
1.74
1.51
1.72
1.65
1.61
1.62
4.08
Revenue per Share
0.25
0.28
0.31
0.63
0.2
0.23
0.27
0.3
0.41
0.44
0.22
-0.04
0.17
0.14
0.13
0.16
0.37
Basic EPS, GAAP
0.28
0.23
-0.03
0.34
0.07
0.06
0.08
0.1
-0.45
-0.51
-0.15
-0.39
0.14
0.12
-0.41
0.2
-0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.03
0.07
0.09
0.12
0.06
- -
- -
- -
- -
- -
- -
Dividend per Share
0.89
1.1
1.35
2.18
0.55
0.71
0.93
0.13
0.13
0.13
0.13
0.13
0.13
0.13
0.13
0.13
0.16
Book Value per Share
1.09
1.46
1.3
2.87
1.52
1.6
1.42
1.54
0.76
1
0.71
0.78
1.16
1.65
2.17
2.7
1.55
Tangible Book Value per Share
493
493
493
493
2,995
3,321
3,321
3,258
3,208
3,203
3,187
3,445
3,481
3,728
3,762
3,896
493
Basic Weighted Avg Shares
955
1,341
1,774
2,515
2,544
2,563
2,918
3,815
5,173
6,358
5,540
5,200
5,982
6,143
6,061
6,308
2,010
Sales/Revenue/Turnover
16.97
15.06
12.14
16.45
28.49
32.42
31.35
28.59
29.32
27.37
21.94
5.44
15.95
16.75
21.3
19.9
12.08
Operating Margin (%)
45
70
79
100
110
115
141
250
317
456
511
582
671
702
791
839
88
Depreciation Expense
124
136
152
310
606
755
892
981
1,303
1,396
707
-134
605
533
472
619
181
Net Income, GAAP
22.29
23.04
17.35
14.41
15.31
14.86
8.28
12.16
11.37
17.13
25.36
- -
12.91
23
23.14
25.3
11.43
Effective Tax Rate (%)
12.94
10.15
8.55
12.35
23.8
29.44
30.56
25.73
25.19
21.96
12.76
-2.58
10.11
8.67
7.79
9.81
9.02
Profit Margin (%)
386
436
39
349
2,638
4,026
2,908
2,641
472
3,819
2,736
3,066
1,299
2,565
2,539
5,297
110
Working Capital
30
1
2
9
1
- -
- -
- -
848
4,510
4,339
4,228
2,265
3,228
2,736
2,723
48
LT Debt
1,095
1,248
1,404
1,898
5,038
5,800
6,562
6,896
7,934
8,920
8,099
9,114
11,042
13,528
15,754
18,359
1,495
Total Equity
11.08
10.98
10.42
15.29
14.96
11.87
11.29
10.41
11.07
9.01
5.02
- -
4.24
3.72
4.07
3.43
11.38
Return on Invested Capital (%)
21.39
15.6
14.07
19.61
31.37
29.91
23.37
24.83
28.75
21.49
10.48
- -
9.88
10.29
6.55
8.48
27.43
Return on Capital (%)
29.77
27.82
25.09
35.69
44.73
37.8
32.7
55.73
307.18
331.67
168.52
-30.76
132.52
112.95
97.07
123.14
223.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'11
Mar'13
Jun'13
ST Debt
454
556
541
LT Borrowings
2
4
48
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
493
493
493
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'11
Mar'13
Jun'13
Total Current Assets
930
1,031
1,083
Cash, Cash Equivalents & STI
331
354
398
Accounts Receivable, Net
455
506
512
Inventories
105
105
112
Total Current Liabilities
891
978
973
Payables & Accruals
- -
- -
- -
ST Debt
454
556
541
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.57%
17.84%
16.54%
Free Cash Flow
-108.87%
-115.52%
-150.65%
Net Income, GAAP
-64.25%
-132.25%
31.12%
Sales/Revenue/Turnover
10.46%
2.87%
4.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,143
2024
- -
- -
- -
- -
6,061
2025
- -
- -
- -
- -
6,308

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.14
2024
- -
- -
- -
- -
0.13
2025
- -
- -
- -
- -
0.16

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Qingdao Baheal Medical Inc. (301015.SZ)
Firebrick Pharma Limited (FRE.AX)
NanJing Pharmaceutical Company Limited (600713.SS)
Orion Oyj (ORINF)
Tdspharm (464280.KQ)
Bayer Aktiengesellschaft (BAYN.DE)
Business
Luye Pharma Group Ltd. (LYPHF) develops, manufactures, markets and sells innovative pharmaceutical products focused on central nervous system disorders, oncology, cardiovascular diseases, alimentary tract and metabolism conditions, orthopedics, neurology, gastroenterology, hepatology and gynecology; core offerings include extended-release injectable suspensions such as Erzofri (paliperidone palmitate), Rykindo (risperidone) and Ruiketuo (risperidone microspheres), transdermal drug delivery systems including Rivastigmine Twice Weekly Transdermal Patch and Rotigotine Transdermal Patch (Rotigotine Luye), liposomes and targeted therapies like Lipusu (paclitaxel liposome), Boyounuo (bevacizumab), Boyoubei/Boluojia (denosumab), Baituowei (goserelin microspheres), biopharmaceuticals such as Zepzelca (lurbinectedin), Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets), Jinyouping (rotigotine microspheres for injection), Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets), Boyouping (dulaglutide injection) and Boyoujing (aflibercept intravitreous injection), alongside Seroquel/Seroquel XR, Xuezhikang and other drugs leveraging long-acting, sustained-release, liposome, transdermal and novel compound technologies through subsidiaries like Shandong Boan Biotechnology. Founded in 1994 and headquartered in Yantai, Shandong Province, China, the company operates R&D centers in China, the U.S. and Europe, eight GMP-compliant manufacturing sites including seven in China and one in Germany, and commercializes over 30 products across more than 80 countries and regions encompassing China, the U.S., Europe, Japan and emerging markets. Recent developments encompass multiple new drug approvals from 2021-2025 including 15 innovative therapies in the U.S., Europe, Japan and China such as Rivastigmine Twice Weekly Transdermal Patch in Japan (2025), Erzofri in the U.S. (2024) and six China approvals in 2024; FDA clearance of IND for next-generation CNS candidate LY03017 targeting Alzheimer's disease psychosis, Parkinson's disease psychosis and schizophrenia negative symptoms (November 2025); upgrade of international innovation strategy to Version 3.0 driven by in-house development and business development operations with new product sales up 32% in 2025 half-year results; strategic investment in Shenzhen Luye to advance oncology R&D, market access and collaborations (July 2024); and ongoing Phase 3 enrollment for Ruoxinlin and Phase 1 initiation for LY03021.